Document |
Document Title |
WO/2009/014680A2 |
The present invention provides polymorphic forms of dolasetron base and methods for their use and preparation.
|
WO/2009/014679A1 |
Provided are crystalline forms of dolasetron trifluoroacetate, methods for their preparation, and their use in preparing dolasetron mesylate.
|
WO/2008/154243A1 |
A method of preparing a tetrabenazine compound (TBZ compound) having structure I comprising the steps of reacting a nucleophilic alkenyl species with aldehyde compound II and oxidizing the resultant allylic alcohol to provide enone III. ...
|
WO/2008/128431A1 |
The invention relates to l-stepholidine (l-SPD) derivant described as general formula (I) and its producing method. Said l-SPD derivatives and pharmacological acceptable salts, crystalline hydrates, solvates thereof have a double pharmac...
|
WO/2008/096777A1 |
It is intended to provide a pharmaceutical composition useful as a therapeutic agent for irritable bowel syndrome (IBS). As a result of intensive studies of a therapeutic agent for IBS, the present inventors confirmed that N-(1H-tetrazol...
|
WO/2008/082715A2 |
Peptidyl sensors comprise a metal-binding peptide and one or two kinase recognition sequences with a hydroxyamino acid that can be phosphorylated in the presence of a kinase.
|
WO/2008/040192A1 |
The present invention provides 13,13a-dihydroberberine derivatives as shown below, their physiologically acceptable salts, use and pharmaceutical composition comprising the said derivatives. The said 13,13a-dihydroberberine derivatives a...
|
WO/2008/030226A1 |
A naphthopyran compound represented by the formula (I): wherein: n1, n2, p, q is an integer comprised from 0 to 5 inclusive; m is an integer comprised from 0 to 4 inclusive; R1 and R2 represent a group selected from halogen, -Ra, -OH, -O...
|
WO/2008/014661A1 |
The present invention affords tetrahydroprotoberberine compounds listed as formula (I) and their pharmaceutically acceptable inorganic or organic salts, crystallized hydrates, solvates and medicinal compositions. In the formula (I), R1, ...
|
WO/2008/015516A1 |
Disclosed are compounds of Formula (1), pharmaceutical compositions containing compounds of Formula (1), and the use of compounds of Formula (1) to treat central nervous system disorders, including schizophrenia and other psychotic disor...
|
WO/2007/093366A1 |
The invention relates to aminoalcohol-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least ...
|
WO/2007/094548A2 |
The present invention relates to a berberrubine derivative having superior antifungal activity, more particularly to a berberrubine derivative having inhibitory activity against chitin synthase, which participates in the synthesis of chi...
|
WO/2007/067478A2 |
Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondyli...
|
WO/2007/045987A1 |
New derivatives of 4-aminoquinoline which have a general formula A-X-Y-T where A is a 4-aminoquinolinic nucleus, X and Y are spacers and T represents a nitrogenous ring or an aminic group, substituted if necessary. These are powerful ant...
|
WO/2007/006212A1 |
The present invention relates to tetraliydroprotoberberines of the formula (I) and the physiologically acceptable salts thereof. The invention also relates to the use of the compounds of the formula (I) or pharmaceutically acceptable sal...
|
WO/2006/082030A1 |
New 4-aminoquinoline derivatives having the general formula (I) wherein R, M, X, Y and T have the meaning described in the specification, as potent antimalarials active also on chloroquine-resistant Plasmodium falciparum malaria strains.
|
WO/2006/069512A1 |
The invention discloses a method for preparing dehydrocavidine (fig.1), dehydroapocavidine or compositions containing dehydrocavidine and dehydroapocavidine, comprising the steps of isolating and purifying the quaternary ammonium compone...
|
WO/2005/123671A1 |
A pyrrole derivative represented by the general formula (1): (wherein R1 represents hydrogen or C1-4 alkyl; R2 represents C1-10 alkyl, C3-10 cycloalkyl, methylenedioxyphenyl, 1,2-ethylenedioxyphenyl, 1,3-propylenedioxyphenyl, etc.; R3 an...
|
WO/2005/117242A1 |
The object of the invention is a method and installation means for installing an electrical machine, particularly for installing a rotor within a stator. According to the invention, two or more spacer elements (32) are fitted on the oute...
|
WO/2005/099688A2 |
There is provided a CRF receptor antagonist comprising a compound of the formula (I): A-W-Ar wherein, A is a group represented by the formula (A1) or (A2) (wherein, ring Aa is a 5-or 6-membered ring which may be further substituted; ring...
|
WO/2005/077946A1 |
The invention provides novel isomers of dihydrotetrabenazine, individual enantiomers and mixtures thereof wherein the dihydrotetrabenazine is a 3,11 b-cis- dihydrotetrabenazine. Also provided are methods for the preparation of the novel ...
|
WO/2005/077932A2 |
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q and Y are defined in the specification.
|
WO/2005/069894A2 |
The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sen...
|
WO/2005/030791A2 |
The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
|
WO/2004/104000A1 |
A novel compound capable of selectively acting on cannabinoid receptor, especially peripheral receptor; and a medical drug composition thereof. In particular, a tricyclic condensed ring compound of the general formula: (I) (wherein the c...
|
WO/2004/082606A2 |
This invention relates to fused pyrrole compounds of Formula (I), and pharmaceutically acceptable salts and prodrugs thereof, wherein V1, V2, V3, V4, R1, R2, R3, W1 and W2 are as defined herein. The compounds of this invention may be use...
|
WO/2004/076411A2 |
The present invention is directed to compounds of formulae (I and II) (wherein A, D, E. X, l, m, n and R1 through R18 are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are u...
|
WO/2004/056821A2 |
The present invention relates to novel quinolizidine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
|
WO/2004/037213A2 |
Novel and nonobvious compounds that function, alone or in combination, as nuclear hormone receptors for the stimulation and/or improvement of murine, mammalian skin. Specifically, beta-ionol analog and fatty acid analog compounds that ar...
|
WO/2004/026864A1 |
This invention relates to compounds of the formula 1 wherein X, Y, Z, A, R', R2, R3, R4, R9, W' and W2 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous sys...
|
WO/2004/014893A2 |
Compounds of the following formula (I) are effective antimicrobial agents.
|
WO2002080164A9 |
An optical recording medium having at least a recording layer 11 and a light transmitting layer 13 formed on a substrate 10, in which the recording layer 11 is made of an organic material for absorbing an incident light of wavelength of ...
|
WO/2003/104228A1 |
The invention relates to the use of benzo[c]quinolizinium derivatives for treating diseases that are linked to smooth muscle cell constriction, such as hypertension and asthma.
|
WO/2003/099815A1 |
The invention relates to the new arginine salt forms of RS-(±)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-m
ethyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-met
...
|
WO/2003/088917A2 |
The present invention relates to methods for identifying compounds useful for regulating TNF-alpha levels and/or activity. The invention also relates to methods for decreasing TNF-alpha levels and/or activity. Compounds and compositions ...
|
WO/2003/084956A1 |
The invention concerns derivatives of formula (I), wherein R1 represents -OH, (C1-C5) alkoxy, carboxyl, (C2-C6) alkoxycarbonyl, -NR5R6, -NH-SO2-Alk, -NH-SO2-Ph, -NH-CO-Ph, -N(Alk)-CO-Ph, -NH-CO-NH-Ph, -NH-CO-Alk, -NH-CO2-alk,-O-(CH2)n-cA...
|
WO/2003/082866A1 |
The invention provides a compound of formula I, wherein X, Z, R1 to R10, R15, R16, m, n, r and t are as defined in claim 1, or a pharmaceutically acceptable salt or ester thereof, useful as an alpha-2 antagonist. The compounds of formula...
|
WO/2003/080595A1 |
The invention relates to specifically photochromic 3H-naphtho[2,1-b]-pyran derivatives of formula (I), where the groups R1-R7 and B' have the meanings given in the description and use thereof in plastics of all types, in particular for o...
|
WO/2003/070277A1 |
It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having a cannabinoid receptor agonism shows an antipruritic effect.
|
WO/2003/070166A2 |
The invention provides novel tyloindicines analogues and related processes, pharmaceutical compositions, and methods. The novel tyloindicines are useful in a wide variety of antiviral, antineoplastic, antibacterial, and anti-inflammatory...
|
WO/2003/055856A2 |
The present application describes novel bicyclic lactam derivatives of formula (I) or pharmaceutically acceptable salt forms th ereof, wherein A, B, C, D, R1, and R2 are defined in the present specification, which are useful as metallopr...
|
WO/2003/055881A1 |
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or pr...
|
WO/2003/051875A1 |
The present invention relates to derivatives of berberrubine and the salts thereof for antibacterial and antifungal agents, more specifically 9-&Ogr -alkyl berberrubine derivatives represented by the following Formula (I): and the salts ...
|
WO/2003/029253A1 |
4−Oxoquinolizine antimicrobials having 2−pyridone skeleton as partial structure are provided, which have potent antimicrobial activity against Gram−positive and −negative bacteria and anaerobic bacteria. The antimicrobials are co...
|
WO/2003/019697A2 |
The invention relates to an organic electroluminescent device which contains 2,5-diaminoterephthalic acid derivatives of formula 1a as emitter substances in one or several emitter layers in a pure or doped manner. The ring A is a triple ...
|
WO/2003/015517A1 |
The present invention provides compositions and methods for controlling an helminth or arthropod pest. In a preferred embodiment of the invention provided herein, the compositions comprise compounds which alter the 5-HT¿3? receptor of t...
|
WO2001085095B1 |
The invention relates to the new arginine salt forms of S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-met
hyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations...
|
WO/2002/090342A1 |
A chromene compound which typically is that represented by the following formula. (1) This chromene compound in a colored state has two absorption bands in the wavelength regions of from 440 to 500 nm and from 570 to 630 nm, wherein the ...
|
WO/2002/089128A1 |
An optical data storage medium containing a diaza hemicyanine dye as the light-absorbing compound in the information layer A b s t r a c tAn optical data storage medium containing a preferably transparent substrate which has optionally a...
|
WO/2002/086879A1 |
The invention relates to an optical data support, comprising a preferably transparent substrate, optionally already coated with one or several reflective layers, with an information layer, which may be written to by means of light, optio...
|